Scholarlink

Background <p>Androgenetic alopecia (AGA) is a common non-scarring alopecia with substantial psychosocial burden. Minoxidil and 5α-reductase inhibitors remain standards of care but require prolonged adherence and do not fully address the dermal microenvironment.</p> Objective <p>To evaluate efficacy and safety of intradermal 10% glucose combined with non-cross-linked hyaluronic acid (NHA) versus NHA alone for scalp hair regrowth.</p> Methods <p>In this prospective, single-center, randomized, evaluator-blinded pilot study, 40 adults with mild-to-moderate AGA (Norwood–Hamilton II–IV or Ludwig I–II) were randomized 1:1 to receive intradermal 10% glucose + NHA&#xa0;(Sihler G, Sihler Inc., Korea) or NHA alone. Participants underwent five sessions at 3-week intervals (weeks 0–12). This pilot study was not prospectively registered. The primary end point was change in terminal hair density (hairs/cm<sup>2</sup>) in a fixed target area from baseline to week 18. Secondary outcomes included hair shaft diameter, global photographic assessments, responder rates, and patient-reported outcomes.</p> Results <p>Thirty-eight participants completed the study (19 per group). At week 18, mean terminal hair density increased by + 19.3 ± 8.1 hairs/cm<sup>2</sup> with glucose+NHA and by + 6.2 ± 7.5 hairs/cm<sup>2</sup> with NHA alone (between-group difference 13.1 hairs/cm<sup>2</sup>; 95% CI 7.6–18.7; <i>p </i>&lt; 0.001). Mean hair shaft diameter increased by + 12.8% ± 6.9 versus + 4.1%±6.1 (<i>p </i>= 0.002). Responder rates (≥ 15% density increase) were 74% versus 26% (<i>p </i>= 0.003). Adverse events were mild and transient; no serious events occurred.</p> Conclusion <p>In this pilot RCT, intradermal 10% glucose combined with NHA produced greater improvements in objective and subjective hair outcomes than NHA alone, with a favorable shortterm safety profile. Larger, longer trials are warranted.</p> Level of Evidence II <p>This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors <a href="http://www.springer.com/00266">www.springer.com/00266</a>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Intradermal Injections of 10% Glucose (Sihler G) for Scalp Hair Regrowth: A Randomized, Evaluator-Blinded Pilot Study

  • 期刊论文

  • 发表日期：

    2026年7月10日

查看全文
  • Kyu-Ho Yi,
  • Olena Sydorchuk,
  • Suyeon Lee,
  • Mariya Sobchyshyn,
  • Tae-Hyun Kim,
  • Sa Rang Lee,
  • Sijun Park,
  • Yoon Chang-Il,
  • Lee Kyu-Eun

摘要

Background

Androgenetic alopecia (AGA) is a common non-scarring alopecia with substantial psychosocial burden. Minoxidil and 5α-reductase inhibitors remain standards of care but require prolonged adherence and do not fully address the dermal microenvironment.

Objective

To evaluate efficacy and safety of intradermal 10% glucose combined with non-cross-linked hyaluronic acid (NHA) versus NHA alone for scalp hair regrowth.

Methods

In this prospective, single-center, randomized, evaluator-blinded pilot study, 40 adults with mild-to-moderate AGA (Norwood–Hamilton II–IV or Ludwig I–II) were randomized 1:1 to receive intradermal 10% glucose + NHA (Sihler G, Sihler Inc., Korea) or NHA alone. Participants underwent five sessions at 3-week intervals (weeks 0–12). This pilot study was not prospectively registered. The primary end point was change in terminal hair density (hairs/cm2) in a fixed target area from baseline to week 18. Secondary outcomes included hair shaft diameter, global photographic assessments, responder rates, and patient-reported outcomes.

Results

Thirty-eight participants completed the study (19 per group). At week 18, mean terminal hair density increased by + 19.3 ± 8.1 hairs/cm2 with glucose+NHA and by + 6.2 ± 7.5 hairs/cm2 with NHA alone (between-group difference 13.1 hairs/cm2; 95% CI 7.6–18.7; p < 0.001). Mean hair shaft diameter increased by + 12.8% ± 6.9 versus + 4.1%±6.1 (p = 0.002). Responder rates (≥ 15% density increase) were 74% versus 26% (p = 0.003). Adverse events were mild and transient; no serious events occurred.

Conclusion

In this pilot RCT, intradermal 10% glucose combined with NHA produced greater improvements in objective and subjective hair outcomes than NHA alone, with a favorable shortterm safety profile. Larger, longer trials are warranted.

Level of Evidence II

This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.